 Adrenergic Uptake Inhibitors
"Adrenergic Uptake Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
| Descriptor ID |
D018759
|
| MeSH Number(s) |
D27.505.519.562.437.050 D27.505.519.625.050.601 D27.505.519.625.600.050 D27.505.696.577.050.601 D27.505.696.577.600.050
|
| Concept/Terms |
Adrenergic Uptake Inhibitors- Adrenergic Uptake Inhibitors
- Inhibitors, Adrenergic Reuptake
- Reuptake Inhibitors, Adrenergic
- Uptake Inhibitors, Adrenergic
- Adrenergic Reuptake Inhibitors
- Inhibitors, Adrenergic Uptake
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic Uptake Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic Uptake Inhibitors".
This graph shows the total number of publications written about "Adrenergic Uptake Inhibitors" by people in this website by year, and whether "Adrenergic Uptake Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2008 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2012 | 0 | 1 | 1 | | 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Adrenergic Uptake Inhibitors" by people in Profiles.
-
Witek N, Comella C. Valbenazine in the treatment of tardive dyskinesia. Neurodegener Dis Manag. 2019 04; 9(2):73-81.
-
Tavares AA, Barret O, Batis J, Alagille D, Koren A, Papin C, Kudej G, Nice K, Kordower JH, Cosgrove KP, Kloczynski T, Brenner E, Seibyl J, Tamagnan G. Kinetic modeling and occupancy measures of the norepinephrine transporters in baboons using single photon emission computed tomography with (123)I-INER. Synapse. 2013 Jan; 67(1):30-41.
-
Thompson VB, Koprich JB, Chen EY, Kordower JH, Terpstra BT, Lipton JW. Prenatal exposure to MDMA alters noradrenergic neurodevelopment in the rat. Neurotoxicol Teratol. 2012 Jan-Feb; 34(1):206-13.
-
Simon NM, Kaufman RE, Hoge EA, Worthington JJ, Herlands NN, Owens ME, Pollack MH. Open-label support for duloxetine for the treatment of panic disorder. CNS Neurosci Ther. 2009; 15(1):19-23.
-
Davidson J, Allgulander C, Pollack MH, Hartford J, Erickson JS, Russell JM, Perahia D, Wohlreich MM, Carlson J, Raskin J. Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol. 2008 Aug; 23(6):519-26.
-
Rademacher DJ, Napier TC, Meredith GE. Context modulates the expression of conditioned motor sensitization, cellular activation and synaptophysin immunoreactivity. Eur J Neurosci. 2007 Nov; 26(9):2661-8.
-
Zajecka JM, Albano D. SNRIs in the management of acute major depressive disorder. J Clin Psychiatry. 2004; 65 Suppl 17:11-8.
-
Hoehn-Saric R, Ninan P, Black DW, Stahl S, Greist JH, Lydiard B, McElroy S, Zajecka J, Chapman D, Clary C, Harrison W. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry. 2000 Jan; 57(1):76-82.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|